Log in using OpenID

Acromegaly Treatment Market

Acromegaly Treatment Market - Size, Share,
Growth, Outlook, and Opportunity Analysis,
Acromegaly is a rare disorder caused due to the excess production of growth hormone by the
pituitary gland, affecting a patient’s physical appearance and internal organs. It is usually caused by
benign pituitary tumor (adenoma), however, in rare cases acromegaly symptoms can be observed
due to ineffective control of growth hormone-secreting cells by hypothalamus. Abnormal enlargement
of hands, arms, feet, legs, and head, and gradual changes in facial features such as eye-brow, lower
jaw, and nose are visible symptoms of this disorder. Untreated acromegaly leads to serious and life
threating complications such as cardiomyopathy and ventricular arrhythmia. Blood test to measure
levels of growth hormones or insulin-like growth factor and imaging of tumors through MRI scan and
CT scan are commonly used diagnostic approaches to detect acromegaly. Some medications are
90% effective in shrinking tumor, however, success rate of type of treatment varies based on age,
health or medical history of patients. According to the American Society of Clinical Oncology (ASCO),
14,230 individuals of the U.S. were diagnosed with pituitary gland tumor in 2017, of which majority
are benign tumor. Furthermore, in 2017, the National Organization for Rare Disorders estimated the
prevalence rate of acromegaly as 50-70 person per million and 3 new cases occurs per million every
year, which is expected to increase the demand for acromegaly treatment market.
Request Sample Copy of Research Report:
Market Driver:
New drugs in the market widens the choice of therapies for doctors and patients. In 2017,
Midatech Pharma PLC submitted clinical trial application in human study of Q-Octreotide
(MTD201) programme in cancer and acromegaly, and now it has received oral confirmation from
Polish regulators for its approval in January 2018. Furthermore, Chiasma Inc’s new oral
maintenance therapy for acromegaly treatment named Mycapssa, which has completed an
international Phase 3 trial and further conducting an international Phase 3 clinical trial under a
protocol accepted by the European Medicines Agency (EMA) for adult patients with acromegaly is
also expected to boost growth of acromegaly treatment market over the forecast period.
Expiration of drug patents during the forecast period can hamper the market temporarily.
As acromegaly is a non-preventable disease, early detection of the disease will help to cure the
disease symptoms. Increasing awareness to differentiate between acromegaly and other
disorders like gigantism, Marfan syndrome, and Pachydermoperiostosis, and further detecting
the symptoms and diagnosing it will help in propelling the acromegaly treatment market growth.
For instance, Acromegaly Awareness Day was celebrated on November 1, 2017 for the first time
by World Alliance of Pituitary Organization (WAPO) and Pituitary Network Association to increase
awareness on diagnosing the symptoms of this disease without any delay. Some foundation
provided financial assistance to medicare patients suffering with acromegaly. For instance, in
December 2017, HealthWell Foundation launched a new fund scheme where it provided a fund of
US$ 10,000 for a 12-month grant to acromegaly patients who have annual household incomes up
to 400 percent of the federal poverty level. Such funding programs will provide financial ease to
the patients suffering from acromegaly, which in turn will propel growth of acromegaly treatment
market. In 2017, Crinetics Pharmaceuticals, Inc. was awarded Phase IIB Small Business
Innovation Research (SBIR) grant of up to US$ 2.8 million from National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) for the
development of company’s orally-available, non-peptide somatostatin agonist drug candidate,
CRN00808 that can be used for the treatment of acromegaly.
Report includes chapters which deeply display the following deliverable about industry :
• Acromegaly Treatment Market Research Objective and Assumption
• Acromegaly Treatment Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Acromegaly Treatment Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value
Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Acromegaly Treatment Market Market, By Regions
• Acromegaly Treatment Market Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Acromegaly Treatment Market Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Acromegaly Treatment Market Market Manufacturing Cost Analysis including Key Raw Materials
and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Acromegaly Treatment Market Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Acromegaly Treatment Market - Competitors:
Pfizer Inc., Novartis Pharma AG, GlaxoSmithKline plc, Midatech Pharma PLC,
Strongbridge Biopharma plc, Chiasma Inc, Aegis Therapeutics LLC, Amryt Pharma plc,
Antisense Therapeutics Ltd, Crinetics Pharmaceuticals Inc, Dauntless Pharmaceuticals
Inc, and Ipsen Biopharmaceuticals Inc. are the major players involved in acromegaly
treatment market.
Inquire Here Before Purchase:
Acromegaly Treatment Market Dynamics:
By Disease Type:
• Ectopic Acromegaly
• Pseudo Acromegaly
By Drug Class:
Somatostatin Analogs (SSAs)
Somatuline Depot (Lanreotide)
Others SSAs
Dopamine Agonists (DAs)
Bromocriptine Mesylate (Parlodel)
Others DAs
Growth Hormone Receptor Antagonist (GHRAs)
Somavert (Pegvisomant)
By Route of Administration:
• Oral
• Parenteral
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Rushikesh83   documents Email
Health and Medicine
File Size
170 KB
Report inappropriate content